Cargando…
Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines
Live viral vectors that express heterologous antigens of the target pathogen are being investigated in the development of novel vaccines against serious infectious agents like HIV and Ebola. As some live recombinant vectored vaccines may be replication-competent, a key challenge is defining the leng...
Autores principales: | Kochhar, Sonali, Excler, Jean-Louis, Bok, Karin, Gurwith, Marc, McNeil, Michael M., Seligman, Stephen J., Khuri-Bulos, Najwa, Klug, Bettina, Laderoute, Marian, Robertson, James S., Singh, Vidisha, Chen, Robert T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535369/ https://www.ncbi.nlm.nih.gov/pubmed/30497831 http://dx.doi.org/10.1016/j.vaccine.2018.08.085 |
Ejemplares similares
-
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
por: Gurwith, Marc, et al.
Publicado: (2020) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
por: Kochhar, Sonali, et al.
Publicado: (2020) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines
por: Kochhar, Sonali, et al.
Publicado: (2020) -
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains
por: Condit, Richard C., et al.
Publicado: (2016) -
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
por: Condit, Richard C, et al.
Publicado: (2020)